SOMNOMED LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.22 AUD | +7.32% |
|
+4.76% | -56.00% |
| Sales 2024 * | 94.07M 60.36M | Sales 2025 * | 110M 70.89M | Capitalization | 29.94M 19.21M |
|---|---|---|---|---|---|
| Net income 2024 * | -2M -1.28M | Net income 2025 * | - | EV / Sales 2024 * | 0.3 x |
| Net cash position 2024 * | 2.07M 1.33M | Net cash position 2025 * | 6.55M 4.2M | EV / Sales 2025 * | 0.21 x |
| P/E ratio 2024 * |
-6.88
x | P/E ratio 2025 * |
-16.9
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on SomnoMed Limited
| 1 day | +7.32% | ||
| 1 week | +4.76% | ||
| Current month | -42.86% | ||
| 1 month | -42.11% | ||
| 3 months | -55.10% | ||
| 6 months | -62.71% | ||
| Current year | -56.00% |
1 week
0.20
0.26
1 month
0.200.39
Current year
0.200.52
1 year
0.201.04
3 years
0.202.65
5 years
0.203.44
10 years
0.204.08
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 20-08-23 | |
Karen Borg
CEO | Chief Executive Officer | - | 20-11-25 |
Darren Collins
DFI | Director of Finance/CFO | - | 23-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hamish Corlett
BRD | Director/Board Member | - | 18-04-30 |
Guy Russo
CHM | Chairman | 65 | 20-08-23 |
Karen Borg
CEO | Chief Executive Officer | - | 20-11-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.22 | +7.32% | 244,685 |
| 24-04-18 | 0.205 | -4.65% | 1,085,992 |
| 24-04-17 | 0.215 | +2.38% | 335,303 |
| 24-04-16 | 0.21 | -2.33% | 262,429 |
| 24-04-15 | 0.215 | -4.44% | 517,468 |
Delayed Quote Australian S.E., April 19, 2024 at 02:10 am EDT
More quotes
SomnoMed Limited is an Australia-based company, which is engaged in producing and selling devices for the oral treatment of sleep-related disorders. The Company provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is focused on the commercialization of the SomnoDent and other oral devices for sleep-related disorders. The Companyâs segments include North America, Europe, Asia Pacific, CORE, and RSS. Its SomnoDent product line includes SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, SomnoDent Fusion, Herbst Advance Elite and Herbst Advance. Its SomMorning Repositioner is designed to help return their mandible back to its pre-treatment centric position. Its SomnoBrux Michigan splint is a custom fit, acrylic splint (dental guard) for upper teeth designed to protect the teeth from grinding and scraping during Bruxism. It also offers SomTabs, which are cleaning tablets that are developed to clean oral appliances.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.22
AUD
Average target price
1.26
AUD
Spread / Average Target
+472.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.00% | 17.96M | |
| -2.53% | 183B | |
| -3.52% | 105B | |
| +5.33% | 51.77B | |
| +16.43% | 47.29B | |
| -1.73% | 40.2B | |
| +5.66% | 27.62B | |
| -2.01% | 25.51B | |
| +9.84% | 24.73B | |
| -1.87% | 24.52B |
- Stock Market
- Equities
- SOM Stock
